{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Enzalutamide",
        "type": {
          "id": "86c7022c-eef3-4b4b-b6b2-227c3c943f7d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "77f995d4-7e1f-43dd-924a-b3f05cfe9fa9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A second generation androgen receptor (AR) inhibitor",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "eafa896d-b7b3-4fed-9c16-eee471f14547",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "f674f483-032c-4342-8817-7b5411e4ba82",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules identical in appearance to enzalutamide",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Androgen Deprivation Therapy (ADT)",
        "type": {
          "id": "43a7faae-52a8-45dc-859c-b30a061db927",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "ae24ac70-7840-43bd-b77e-a718b9399b75",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "LHRH agonist or antagonist or history of bilateral orchiectomy",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Docetaxel",
        "type": {
          "id": "a0d53e3e-80ea-4c3e-9ba9-b472f0a9e10f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "2961f7c9-27bb-4bd9-89d2-7635ffb5be8b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Up to 6 cycles permitted if completed within 2 months of Day 1"
      },
      {
        "id": "int_5",
        "name": "5-alpha reductase inhibitors",
        "type": {
          "id": "98e36e2b-0fba-4463-a175-97bf067555c7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "524255f3-088d-4dc0-85d1-7fc69458cdd9",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited (e.g., finasteride, dutasteride)"
      },
      {
        "id": "int_6",
        "name": "Estrogens",
        "type": {
          "id": "745ef72e-6aa4-481d-af87-d0e3930844cd",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "edb36484-d961-4d8b-920d-320ddc189797",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited"
      },
      {
        "id": "int_7",
        "name": "Cyproterone acetate",
        "type": {
          "id": "5c044987-e4c9-459a-a466-aef69cd0aba4",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f1352d05-0204-4d95-ae05-c57f6654b94e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited"
      },
      {
        "id": "int_8",
        "name": "Systemic glucocorticoids",
        "type": {
          "id": "35b7f579-38ea-4719-95a3-4344da789aa3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a85dec08-e3f5-4531-97f6-a5a83b9c163a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited if > 10 mg/day prednisone equivalent for prostate cancer treatment"
      },
      {
        "id": "int_9",
        "name": "Herbal medications",
        "type": {
          "id": "f05a2a8b-37ca-4483-8a69-dbd906d475ca",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "87689908-3233-492d-8143-119c87bcbc18",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited if known hormonal antiprostate cancer activity (e.g., saw palmetto)"
      },
      {
        "id": "int_10",
        "name": "Androgens",
        "type": {
          "id": "a70b2f3d-fbb5-41ef-a1e3-3f644236c5fa",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "eaa510f1-93da-4ffb-842f-4cb4f4e0b59d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited (e.g., testosterone, dihydroepiandrosterone)"
      },
      {
        "id": "int_11",
        "name": "Bisphosphonates or denosumab",
        "type": {
          "id": "6e26a814-4d2c-47f7-98ca-d652e914be38",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "53f4f440-8161-4524-b79c-d3451a548eca",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited unless stabilized for 2 weeks prior to randomization or for osteoporosis"
      },
      {
        "id": "int_12",
        "name": "Strong CYP2C8 inhibitors",
        "type": {
          "id": "677c059e-72f5-4335-b687-e2a15ab7b43d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "345dcae8-7f26-492b-a45f-905bbb7170b2",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Avoided; if necessary, reduce enzalutamide dose to 80 mg (e.g., gemfibrozil)"
      },
      {
        "id": "int_13",
        "name": "Strong/Moderate CYP3A4 inducers",
        "type": {
          "id": "59b37ebc-2862-4221-9f13-4bb8c3d07063",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "cce91b38-c98f-4900-89fe-7658763fc2cf",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Avoided (e.g., carbamazepine, rifampin, St. John’s Wort)"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Enzalutamide capsules",
        "administrableDoseForm": {
          "id": "efcad4fc-b14f-4783-bddb-42afed0c6e30",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "b3c899a9-e77b-459d-bd95-506d00e75739",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0151d406-4eb5-45fd-93b2-02c6514bd487",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "40 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Astellas Pharma Global Development, Inc"
      },
      {
        "id": "prod_2",
        "name": "Placebo capsules",
        "administrableDoseForm": {
          "id": "fec3eaa6-23bb-4a5a-848e-a58439d5ed26",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "f6a1a8f2-eb64-4ecb-b7d4-0726fd696258",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "6296d8fa-dfe4-4ffb-9842-7970e1b83c39",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Astellas Pharma Global Development, Inc"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Standard Enzalutamide Regimen",
        "instanceType": "Administration",
        "dose": "160 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until radiographic disease progression or unacceptable toxicity"
      },
      {
        "id": "admin_2",
        "name": "Reduced Enzalutamide Regimen (Toxicity)",
        "instanceType": "Administration",
        "dose": "120 mg or 80 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "As needed for toxicity management"
      },
      {
        "id": "admin_3",
        "name": "Reduced Enzalutamide Regimen (CYP2C8 Interaction)",
        "instanceType": "Administration",
        "dose": "80 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "During coadministration with strong CYP2C8 inhibitor"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Enzalutamide",
        "instanceType": "Substance",
        "description": "Active pharmaceutical ingredient; formerly MDV3100"
      },
      {
        "id": "sub_2",
        "name": "N-desmethyl enzalutamide",
        "instanceType": "Substance",
        "description": "Major active human metabolite"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 13,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Enzalutamide",
        "role": "Investigational Product",
        "description": "A second generation androgen receptor (AR) inhibitor"
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules identical in appearance to enzalutamide"
      },
      {
        "name": "Androgen Deprivation Therapy (ADT)",
        "role": "Background Therapy",
        "description": "LHRH agonist or antagonist or history of bilateral orchiectomy"
      },
      {
        "name": "Docetaxel",
        "role": "Prior Medication",
        "description": "Up to 6 cycles permitted if completed within 2 months of Day 1"
      },
      {
        "name": "5-alpha reductase inhibitors",
        "role": "Concomitant Medication",
        "description": "Prohibited (e.g., finasteride, dutasteride)"
      },
      {
        "name": "Estrogens",
        "role": "Concomitant Medication",
        "description": "Prohibited"
      },
      {
        "name": "Cyproterone acetate",
        "role": "Concomitant Medication",
        "description": "Prohibited"
      },
      {
        "name": "Systemic glucocorticoids",
        "role": "Concomitant Medication",
        "description": "Prohibited if > 10 mg/day prednisone equivalent for prostate cancer treatment"
      },
      {
        "name": "Herbal medications",
        "role": "Concomitant Medication",
        "description": "Prohibited if known hormonal antiprostate cancer activity (e.g., saw palmetto)"
      },
      {
        "name": "Androgens",
        "role": "Concomitant Medication",
        "description": "Prohibited (e.g., testosterone, dihydroepiandrosterone)"
      },
      {
        "name": "Bisphosphonates or denosumab",
        "role": "Concomitant Medication",
        "description": "Prohibited unless stabilized for 2 weeks prior to randomization or for osteoporosis"
      },
      {
        "name": "Strong CYP2C8 inhibitors",
        "role": "Concomitant Medication",
        "description": "Avoided; if necessary, reduce enzalutamide dose to 80 mg (e.g., gemfibrozil)"
      },
      {
        "name": "Strong/Moderate CYP3A4 inducers",
        "role": "Concomitant Medication",
        "description": "Avoided (e.g., carbamazepine, rifampin, St. John’s Wort)"
      }
    ],
    "products": [
      {
        "name": "Enzalutamide capsules",
        "doseForm": "Capsule",
        "strength": "40 mg",
        "manufacturer": "Astellas Pharma Global Development, Inc"
      },
      {
        "name": "Placebo capsules",
        "doseForm": "Capsule",
        "strength": "0 mg",
        "manufacturer": "Astellas Pharma Global Development, Inc"
      }
    ],
    "substances": [
      {
        "name": "Enzalutamide",
        "description": "Active pharmaceutical ingredient; formerly MDV3100"
      },
      {
        "name": "N-desmethyl enzalutamide",
        "description": "Major active human metabolite"
      }
    ],
    "administrations": [
      {
        "name": "Standard Enzalutamide Regimen",
        "dose": "160 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Until radiographic disease progression or unacceptable toxicity"
      },
      {
        "name": "Reduced Enzalutamide Regimen (Toxicity)",
        "dose": "120 mg or 80 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "As needed for toxicity management"
      },
      {
        "name": "Reduced Enzalutamide Regimen (CYP2C8 Interaction)",
        "dose": "80 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "During coadministration with strong CYP2C8 inhibitor"
      }
    ],
    "devices": []
  }
}